Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523997-18-00

Enrollment

Registered

2026-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Brief summary

Progression free survival rate at week18 (PFS18) assessed by the investigator as per RECIST 1.1., Confirmed ORR, defined as the proportion of participants who have achieved a confirmed CR or PR as assessed by investigator, according to RECIST 1.1

Interventions

None listed

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Progression free survival rate at week18 (PFS18) assessed by the investigator as per RECIST 1.1., Confirmed ORR, defined as the proportion of participants who have achieved a confirmed CR or PR as assessed by investigator, according to RECIST 1.1	—

Outcome results